Abstract: A kit is disclosed for accurately loading a small volume dose of a medication within a syringe and for delivering the small volume dose of the medication at a treatment site. The kit generally includes a loading and delivery system in accordance herewith, a syringe, and a medication. The loading and delivery system includes a syringe delivery ring and a syringe loading guide, which may be used for example, to administer a small volume dose of a medication at the end of an ocular surgery.
Abstract: A kit is disclosed for accurately loading a small volume dose of a medication within a syringe and for delivering the small volume dose of the medication at a treatment site. The kit generally includes a loading and delivery system in accordance herewith, a syringe, and a medication. The loading and delivery system includes a syringe delivery ring and a syringe loading guide, which may be used for example, to administer a small volume dose of a medication at the end of an ocular surgery.
Abstract: The present embodiments provide for simple devices that guide the loading and dispensing of accurate small doses of fluid from standard injection syringes.
Type:
Application
Filed:
August 26, 2020
Publication date:
December 10, 2020
Applicant:
ICON BIOSCIENCE, INC.
Inventors:
Vernon G. WONG, Tan PHAM, William S. WHITE, Glenn T. HUANG, Mae W. HU
Abstract: The present embodiments provide for simple devices that guide the loading and dispensing of accurate small doses of fluid from standard injection syringes.
Type:
Grant
Filed:
June 19, 2018
Date of Patent:
October 13, 2020
Assignee:
ICON BIOSCIENCE, INC.
Inventors:
Vernon G. Wong, Tan Pham, William S. White, Glenn T. Huang, Mae W. Hu
Abstract: The present embodiments provide for a treatment regimen and use of a short-term sustained release liquid formulation of dexamethasone in citrate, wherein a single administration of a minute dosage form into the anterior chamber of the eye provides for anti-inflammatory therapy following cataract surgery.
Type:
Grant
Filed:
June 26, 2018
Date of Patent:
December 25, 2018
Assignee:
ICON BIOSCIENCE, INC.
Inventors:
Vernon G. Wong, William S. White, Mae W. Hu, Glenn T. Huang, Faina Karasina
Abstract: The present embodiments provide for a treatment regimen and use of a short-term sustained release liquid formulation of dexamethasone in citrate, wherein a single administration of a minute dosage form into the anterior chamber of the eye provides for anti-inflammatory therapy following cataract surgery.
Type:
Grant
Filed:
May 23, 2014
Date of Patent:
July 24, 2018
Assignee:
ICON BIOSCIENCE, INC.
Inventors:
Vernon G. Wong, William S. White, Mae W. Hu, Glenn T. Huang, Faina Karasina
Abstract: The present invention provides for injectable pharmaceutical sustained release formulations for delivery of active agents, particularly therapeutic proteins, to the eye. The formulations are biocompatible, biodegradable sustained release formulations comprising low-solubility liquid excipients and relatively small amounts (less than about 10%) of biocompatible, biodegradable polymer such as PLA or PLGA polymers. A unit dose of 5 ?L to 100 ?L of the formulation provides for sustained release of the agent for at least 14 days.
Type:
Grant
Filed:
June 11, 2012
Date of Patent:
November 14, 2017
Assignees:
Ramscor, Inc., Icon Bioscience, Inc.
Inventors:
Vernon G. Wong, Louis L. Wood, Carol Wood, Glenn T. Huang
Abstract: The present embodiments provide for methods of treating elevated intraocular pressure or glaucoma using a sustained release medicament consisting of prostaglandin in benzyl benzoate that is injected intraocularly no more frequently than once every two months.
Type:
Grant
Filed:
February 8, 2016
Date of Patent:
May 2, 2017
Assignee:
Icon Bioscience, Inc.
Inventors:
Vernon G. Wong, Mae W. Hu, Glenn T. Huang
Abstract: The present embodiments provide for methods of treating elevated intraocular pressure or glaucoma using a sustained release medicament consisting of prostaglandin in benzyl benzoate that is injected intraocularly no more frequently than once every two months.
Type:
Grant
Filed:
January 30, 2014
Date of Patent:
March 15, 2016
Assignee:
Icon Bioscience, Inc.
Inventors:
Vernon G. Wong, Mae W. Hu, Glenn T. Huang
Abstract: The present invention provides for injectable pharmaceutical sustained release formulations for delivery of active agents, particularly therapeutic proteins, to the eye. The formulations are biocompatible, biodegradable sustained release formulations comprising low-solubility liquid excipients and relatively small amounts (less than about 10%) of biocompatible, biodegradable polymer such as PLA or PLGA polymers. A unit dose of 5 ?L to 100 ?L of the formulation provides for sustained release of the agent for at least 14 days.
Type:
Application
Filed:
June 11, 2012
Publication date:
May 22, 2014
Applicants:
ICON BIOSCIENCE, INC., RAMSCOR, INC.
Inventors:
Vernon G. Wong, Louis L. Wood, Glenn T. Huang